Differentiating biochemical from clinical heparin resistance in COVID-19.
作者信息
Lisman Ton, Thachil Jecko
机构信息
Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, BA33, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Department of Haematology, Manchester University Hospitals, Oxford road, Manchester, UK.
出版信息
J Thromb Thrombolysis. 2020 Nov;50(4):1015-1016. doi: 10.1007/s11239-020-02259-5.
Abstract
摘要
相似文献
1
Differentiating biochemical from clinical heparin resistance in COVID-19.
J Thromb Thrombolysis. 2020 Nov;50(4):1015-1016. doi: 10.1007/s11239-020-02259-5.
2
Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care.
Thromb Res. 2020 Nov;195:226-227. doi: 10.1016/j.thromres.2020.08.010. Epub 2020 Aug 9.
3
A Case of Covid-19 Patient with Acute Limb Ischemia and Heparin Resistance.
Ann Vasc Surg. 2020 Oct;68:88-92. doi: 10.1016/j.avsg.2020.06.046. Epub 2020 Jun 24.
4
Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.
J Thromb Haemost. 2020 Aug;18(8):2073-2075. doi: 10.1111/jth.14902.
5
The versatile heparin in COVID-19.
J Thromb Haemost. 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821. Epub 2020 Apr 27.
6
Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
Thromb Haemost. 2020 Aug;120(8):1230-1232. doi: 10.1055/s-0040-1712097. Epub 2020 Apr 29.
7
Potential of heparin and nafamostat combination therapy for COVID-19.
J Thromb Haemost. 2020 Jun;18(6):1521-1522. doi: 10.1111/jth.14858. Epub 2020 May 6.
8
Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin.
Sao Paulo Med J. 2020 Jul-Aug;138(4):349-351. doi: 10.1590/1516-3180.2020.0221.r2.22072020.
9
Type and dose of heparin in Covid-19: Reply.
J Thromb Haemost. 2020 Aug;18(8):2063-2064. doi: 10.1111/jth.14870. Epub 2020 May 11.
10
Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy.
Blood Transfus. 2020 Jul;18(4):328. doi: 10.2450/2020.0164-20.
引用本文的文献
1
Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort.
Front Cardiovasc Med. 2022 Oct 6;9:929284. doi: 10.3389/fcvm.2022.929284. eCollection 2022.
2
Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221087692. doi: 10.1177/10760296221087692.
3
Adequate Antithrombin III Level Predicts Survival in Severe COVID-19 Pneumonia.
Cureus. 2021 Oct 6;13(10):e18538. doi: 10.7759/cureus.18538. eCollection 2021 Oct.
4
Heparin - Messias or Verschlimmbesserung?
J Thromb Haemost. 2021 Oct;19(10):2373-2382. doi: 10.1111/jth.15464. Epub 2021 Jul 29.
5
How we approach thrombosis risk in children with COVID-19 infection and MIS-C.
Pediatr Blood Cancer. 2021 Jul;68(7):e29049. doi: 10.1002/pbc.29049. Epub 2021 May 6.
6
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.
Res Pract Thromb Haemost. 2020 Dec 6;5(1):132-141. doi: 10.1002/rth2.12462. eCollection 2021 Jan.
本文引用的文献
1
In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation.
J Thromb Haemost. 2020 Oct;18(10):2646-2653. doi: 10.1111/jth.15043. Epub 2020 Sep 1.
2
Hypoxia-An overlooked trigger for thrombosis in COVID-19 and other critically ill patients.
J Thromb Haemost. 2020 Nov;18(11):3109-3110. doi: 10.1111/jth.15029.
3
Thrombosis and coagulopathy in COVID-19: An illustrated review.
Res Pract Thromb Haemost. 2020 Jul 11;4(5):744-751. doi: 10.1002/rth2.12400. eCollection 2020 Jul.
4
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.
J Thromb Haemost. 2020 Sep;18(9):2215-2219. doi: 10.1111/jth.15016. Epub 2020 Aug 11.
5
Coagulopathy in COVID-19.
J Thromb Haemost. 2020 Sep;18(9):2103-2109. doi: 10.1111/jth.14975. Epub 2020 Jul 21.
6
Heparin resistance in COVID-19 patients in the intensive care unit.
J Thromb Thrombolysis. 2020 Aug;50(2):287-291. doi: 10.1007/s11239-020-02145-0.
7
Monitoring of heparins in antithrombin-deficient patients.
Thromb Res. 2019 Mar;175:8-12. doi: 10.1016/j.thromres.2019.01.007. Epub 2019 Jan 15.
8
Clinical Scenarios for Discordant Anti-Xa.
Adv Hematol. 2016;2016:4054806. doi: 10.1155/2016/4054806. Epub 2016 May 12.
9
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
PLoS One. 2014 Feb 4;9(2):e88390. doi: 10.1371/journal.pone.0088390. eCollection 2014.
10
Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Br J Haematol. 2013 Dec;163(5):666-73. doi: 10.1111/bjh.12593. Epub 2013 Oct 8.
Zotero 插件